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Summary Fourteen patients suffering from advanced colorectal (n = 7), pancreatic (n = 4) or gastric (n = 3) carcinomas received treatment
with microencapsulated octreotide pamoate 90 mg i.m. every 4 weeks (n = 4), 160 mg i.m. every 4 weeks (n = 4) or 160 mg i.m. every 2
weeks (n = 6). Two patients had stable disease, one for 4 and one for 6 months. Plasma insulin-like growth factor (IGF)-I decreased by
49-53%, IGF-11 by 27-37% and total IGF-binding protein (IGFBP)-3 by 16-190/o, whereas IGFBP-1 increased by 35.55%. Insulin and C-
peptide levels decreased by 29-38% and 41-46% respectively. A non-significant decrease in urinary GH secretion and an increase in the
ratio of fragmented to intact IGFBP-3 as well as IGFBP-3 protease activity was seen. The increase in IGFBP-3 fragmentation correlated
negatively with alterations in IGF-I and IGF-II (P< 0.05). We conclude that microencapsulated octreotide administered in doses up to 160 mg
every 2 weeks is well tolerated and has pronounced effects on several components of the IGF system in plasma. In addition, changes in
IGFBP-3 protease actvity because of cancer may contribute to alterations in IGF-I and -Il, indicating the importance of measuring this
parameter in addition to IGFs and IGFBPs when evaluating alterations in IGF-I.
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Advanced gastrointestinal and pancreatic cancers have a grave
prognosis and pose serious problems in medical oncology. Current
systemic treatment options are oflimited value, and new strategies
are needed to improve therapy. Somatostatin analogues are found
to be useful in palliative treatment of certain endocrine gastro-
intestinal tumours (Schally. 1988). In vitro and animal studies have
also shown somatostatin analogues to inhibit the growth of non-
endocrine pancreatic and gastrointestinal tumours (Szepeshazi et
al, 1991; Dy et al. 1992: Qin et al. 1992: Watson et al. 1992).
Although grow%th inhibition by somatostatin analogues may be
a direct effect mediated by specific somatostatin receptors on
tumour cells. such effects could also be achieved through inhibi-
tion of growth factors and growth stimulatory hormones.
Somatostatin analogues inhibit secretion of gastrointestinal
hormones with possible mitogenic effects (Adrian et al. 1981) and
suppress synthesis ofthe insulin-like growth factor (IGF)-I (Pollak
et al. 1989: Figg et al. 1995: Leo et al. 1995) by suppressing
growth hormone (GH) secretion (del Pozo et al. 1986). the main
trophic factor for IGF-I synthesis (Schwander et al. 1983). IGF-I
and -H are important mitogens to many human cancer cell lines in
vitro and altered bioavailability ofthese growth factors may poten-
tially influence tumour growth (Macaulay, 1992).
Clinical studies evaluating the anti-tumour effect of somato-
statin analogues in non-endocrine abdominal cancers have
reported conflicting results (Savage et al. 1987: Klijn et al. 1990:
Friess et al. 1993: Smith et al. 1994. Cascinu et al. 1995). A major
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obstacle to the development of somatostatin analogues in clinical
use has been their short half-lives. demanding three daily injec-
tions (Kutz et al. 1986). In this study we evaluate the tolerability.
clinical effects, pharmacokinetics and effects on plasma IGF-I and
-II of a new microencapsulated formulation ofoctreotide pamoate
in patients suffering from gastrointestinal and pancreatic carci-
nomas. Plasma IGFs are bound to specific IGF-binding proteins
(IGFBPs) acting as carriers and also as modulators of IGF-I bio-
activity in the tissues (Jones and Clemmons. 1995). Most IGF-I
and -H1 circulate in a 150-kDa complex together with an acid-labile
subunit (ALS) and IGFBP-3. and availabilit) of these growth
factors to the tissues may be affected by proteases acting on
IGFBP-3 as substrate (Holly et al. 1993). Thus. apart from deter-
mining plasma IGF-I and -HI together with IGFBP-1 and -3 with
radioimmunoassay (RIA). we measured IGFBPs using Western
ligand blotting and the functional status of IGFBP-3 using
immunoblotting. In addition. we also measured IGFBP-3 protease
activity in the plasma samples.
PATIENTS AND METHODS
Patients
Fourteen patients (eight men and six A-omen) with progressive
locally advanced and/or metastatic adenocarcinomas ofabdominal
origin were studied (Table 1). Any other svstemic anti-cancer
therapy had been terminated at least 4 weeks before inclusion in
the study. All patients had a performance status (WHO) less than 2
and an expected survival of more than 3 months. None of the
patients had any significant medical or surgical disorder apart
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Table 1 C1inical charaeristics of te indvial pabents icluded inte study
Patient number Cohort Prihmaytumouw Age (s) B (kg n-') Previous teatment M loaion(s)
1 1 Pancreatic 45 16.7 None Liver
2 1 Gastric 79 24.6 None Pleura
3 1 Colorectb 61 20.1 ChemotW apy Lung
4 1 Coborectal 74 28.8 Chemothrapy Lung
5 2 Pancreatic 63 24.7 None Locally advanced
6 2 Pancreatic 71 16.3 None Liver, lymph nodes
7 2 Colorectal 65 29.7 Cherotwapy Liver
8 2 Cobrectal 51 22.3 Chemothrapy Liver
9 3 Pancreatic 54 23.7 None Liver
10 3 Gastric 69 22.1 None Liver
11 3 Gastic 68 14.4 None Liver
12 3 Colrectal 57 24.8 Chemothrapy Liver
13 3 Co blt 55 26.4 Chemoterapy Lung
14 3 C doredal 66 22.5 Chemothrapya Lung
a5Fkxxourac and leuovorin.
from their cancer. Median age was 64 years (range 45-79 years)
and body mass index 22.8 kg mr-2 (range 14.4-29.7). The study
was approved by the regional ethics committee. All patients gave
their written inforned consent to participate in the trial.
Treatment schedule
Patients were assigned sequentially to one of three cohorts. The
first cohort received octreotide pamoate (OncoLAR) 90 mg i.m.
every 4 weeks, whereas cohorts 2 and 3 received octreotide
160 mg i.m. every4weeks andevery 2 weeks respectively. Fourto
six patients were enrolled in each cohort, and the firquency of
dose-limiting toxicities (grade 3) should be < 1 in four subjects or
< 2 in six subjects to allow patients to be enrolled in the next
cohort. Thus, four patients were treated in cohorts 1 and 2,
whereas six patients were trated in cohort 3. Physical examina-
tion, evaluation ofadverse effects and standard laboratory evalua-
tions (haematology, chemistry and urine analysis) were performed
weekly until first response evaluation at day 57. Response evalua-
tion was carried out radiologically according to the UICC criteria.
Patients showing either stable disease or an objective response
were offered continuous treatment with octreotide pamoate in the
same dose as they had rceived during the first 8 weeks of the
study with weekly follow-up fortoxicity. Patients in cohorts 1 and
2 notcontinuing maintenance therapy had follow-up visits every 4
weeks, whereas patients in cohort 3 had extended weekly exami-
nations up to day 71 aftercommencing treatment and laterevery 4
weeks.
Bklod and unne sampling
Fasting blood samples for evaluation of the IGF system, insulin
and C-peptide were obtaied in heparinized vials on the morning
ofcommencing treatment and subsequently ondays 15, 29, 57, 71,
99, 127, 155 and 169 during the reatment period. Plasma was
separated by centrifugation and stored at - 20°C until analysis.
Overnight (12 h) urine was collected on the same days forestima-
tion of GH secretion. Serum samples for measurement of
octroide levels were obtained weekly during the study period. At
the day of drug administration additional samples were drawn
before and 1, 2 and 3 h afterinjection.
MaterIas
Human recombinant IGF-I and IGF-II were purchased from
GroPep (Adelaide, Australia). Human recombinant non-glycosyl-
ated IGFBP-3 was a gift from Dr C Maack, Celtrix (Santa Clara,
CA, USA). IGF-I, -II and IGFBP-3 were iodinated using the
chloramine-T mtdho. Labelled peptide was separated from non-
incorporated '251 using AcA 202 columns (BioSepra, Villeneuve,
France) using 1 x 40 cm columns for IGF-I and -II and 1 x 10 cm
columns for IGFBP-3.
Assays
Plasma levels ofIGF-I (Holly et al, 1988) and IGF-lI (Davies et al,
1991) were measured using RIA after acid-acetone extraction.
IGFBP-3 (Cwyfan-Hughes et al, 1993) and IGFBP-1 (Holly et al,
1988) and octreotide (del Pozo et al, 1986) were directly measured
using RIA. Plasma insulin and C-peptide were measured using
RIA kits purchased from Diagnostic Products Corporation (Los
Angeles, CA, USA). Urinary GH was measured by a sensitive RIA
kit obtained from BioMerieux (France) according to the manufac-
turer's instructions.
The IGFBPprofile in the plasma was analysed by Western ligand
blotting (WLB) using a modified version (Coulson et aL 1991) of
the techniquw orginally descnrbedby Hossenlopp (Hossenlopp etaL
1986). IGFBPs were visualized by autoradiography and quantified
using a densitometric scanner (Pharmacia LKB, Uppsala, Sweden).
The IGFBP pattern was compared with the profile of a noml
plasma pool (NP), and samples from each patient were analysed in
the same run for comparson.
AfterWLB the membranes were washed and blocked four tmes
in 10 nm Tris-HCl (pH 7.4) containing 5% milk and 0.2% Tween
20. The membranes were then probed overnight with a polyclonal
specific antiserum against IGFBP-3 purchased from Diagnostic
Systems Laboratories (Webster, TX, USA) at a final dilution of
1: 10000. The membranes were then developed using enhanced
chemiluminescent reagents supplied by Amersham (Aylesbury,
UK) according to the manufacturer's instructions and the films
were subjected to densitometric scanniing.
The IGFBP-3 proteolytic activity in plasma was examined using
a modified version (Frost et al, 1993) of the technique described
by Lamson et al (1991).
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Statistics
Cohort 1 In pevious studies we found plasma levels of IGF-I and -11, and
50 IGFBP-1 to be well fitted to a log normal distribution whereas
IGFBP-3 was found to be nomally distributed (L0nning et al, 1995;
Helle et al, 1996). Thus, parameters are given as their geometrical
40- mean value with 95% confidence intervals of the mean, with the
E exception of IGFBP-3 and plasma octreoide levels when the arith-
metic mean values are given. Correlations between parameters were
X 30- tested for using the Spearman rank correlation test.
0
0 0 20l RESULTS E
co0
a. Tolrability and clinical effects
10 Treatment with octreotide pamoate was well tolerated. Dose-
/ I limiting (grade 3) side-effects were not seen in any ofthe patients.
0 The most common side-effect was dianroea (four events grade
0 10 20 30 40 50 6 1 1-2). One patient complained about dizziness, one experienced
Day oftweamt pain at the injection site and one female patient developed
Cohort 2 alopecia, possibly related to the medication. Owing to sustained
40- diarrhoea (grade 2), one patient treated in cohort 3 terminated
treatment on his own choice after one injection ofoctreotide only.
Eleven out of the 13 evaluable patients were found to have
progressive disease on day 57 (the first response evaluation). One
E patient with pancreatic cancer (cohort 2) had stable disease up to
day 85, whereas one patient with gastric cancer (cohort 3) had
stable disease lasting for 6 months.
° 20- / Although a slight weight loss was observed in most patients,
o | t only one patient lost more than 10% ofhis body weight during the
E study period. One patient had deteriorating liver function at
s0It response evaluation based on serum bilirubin levels (2.5 x upper
a. 1 /| normal range), whereas the other patients had serum levels within
the normal range.
0 Plasma otreotide levels
0 10 20 30 40 50 60
Day ofteatent Mean plasma levels of octreotide during the treatment period are
60 Cohort 3 shown in Figure 1. Peak levels of octreotide at the first day of
injection (data not shown) for all cohorts were generally two to
five times higher (range 2.2-9.9) than plasma levels measuredjust
50- before the next injection. This ratio decreased in all patients after
repeated injections. The lowest plasma level of octreotide
E observed at any time during treatment was 3.4 ng ml-'. No differ-
ence in plasma levels of octreotide between cohorts l and 2 was
o observedduring the treatmentperiod. However, steady-state levels
!30 ofoctreotide for cohorts 2 and 3 were not reached at day 57 when
0 o vr~ most patients terminated treatment. One patient in cohort 3
E 20/ receiving long-term treatment (> 6 months) obtained his highest
a. . rlevel (98.9 ng ml-') at day 13 with a subsequent gradual decline.
10-
Endocrine effects
------ Plasma levels ofIGF-I, IGF-H, IGFBP-l, IGFBP-3 insulin and C-
0 10 20 30 40 50 60 peptide measured using RIA before the first injection on day l and
Day oftreatmet on tratment levels expressed as percentage ofpretreatment values
are shown in Table 2. No differences between the cohorts or diag-
nostic subgroups were observed for any parameter. Accordingly,
FIgue 1 Pma evels of rareide dunngtde ve beFreecoort all data were pooled for statistical analysis. The numberofpatients
gven as mea lvelswWit range. Onlyocteohde beel before qedion are
shown atdays ofdrug abstraton. Vkuesobtained 1, 2 and 3h r available to follow-up beyond day 57 was too small to permit any
irectlon are notickuded statistical analysis ofthese data
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Table 2 Plasma levels of IGF-1, IGF-I1, IGFBP-1, IGFBP-3, insulin, C-peptide and urinary GH excretion at day 1 (before the first injection) and levels at different
time intervals during treatment with octeofide pamoate given as a percentage of pretreatment levels. Values otherthan IGFBP-3 RIA are given as geometrical
mean with 95% confidence intervals
Measured values Values given as % of prereatment (day 1) values
Day 1 15 29 57
IGF-I (ng ml-) 65 (49-5) 51 (43-61) 51 (38-66) 46 (35-61)
IGF-II (ng mMt) 275 (211-358) 73 (64-83) 69 (50-97) 63 (48-83)
IGFBP-1 (ng mi-1) 41 (26-66) 135 (101-181) 150 (112-202) 155 (95-252)
IGFBP-3 RIA (ng ml-') 5293(4560-6026) 85(77-93) 84(79-89) 82(77-93)
IGFBP-3 WLBt 3.2 (1.3-7.6) 66 (53-83) 74(54-98) 51 (34-108)
IGFBP-3 fragmentsc 0.36 (0.24-0.54) 109 (88-135) 98 (85-113) 119 (85-166)
IGFBP-3 protease aivitf 113 (8-22) 121 (85-172) 127 (78-208) 145 (88-240)
Insulin (mlU ml-') 9.8 (7.2-13.3) 71 (48-107) 62 (46-87) 62 (42-90)
C-Peptide (ng ml-') 2.0 (1.4-2.9) 58 (38-87) 54(42-70) 59 (32-109)
GH (ng 12 h) 8.3 (2.2-30.8) 64 (25-162) 35 (8-145) 59 (24-167)
aTwo patients had blood samples obtained at day 22 instead of 29. Theirvalues are included in the day 29 group.'Arbitrary unitscRatio offragmented to total
IGFBP-3. dValue given as percentage of control (day 1) samples with added protease inhibitor (EDTA).
PWtent 1 2 NP
Dayof -3 1 15 22
45-
r ._
31-
21-
Intact-
IGFBP-3- - U,
57 -4 8 15 29 57
FKgure 2 Western ligand blots (above) with corresponding immunoblts for IGFBP-3 (below) in samples from two patients before and dunng treatmnent with
octreotde pamoate. The 42- to 44-kD band on the ligand blot corresponds to the two gycsylation forms of intact IGFBP-3, the 364kDa and 244kDa bands
correspond to IGFBP-2 and IGFBP-4 respectively. The nature of the 30- to 324kDa band was not established. Patient 1 had a rapid progressive disease and an
increase in the ratio offragmented to intac IGFBP-3, whereas patient 2 had a slowerdisease progression and small aiterabons in protease actvity. NP, normal
plasma
Plasma IGF-l levels decreased by 49-54%. whereas IGF-H
decreased by 27-37% at various time intervals on treatment. We
also observed a moderate decrease (16-19%) in immunoreactive
IGFBP-3. IGFBP-1 levels increased by 35-55%. whereas fasting
levels ofinsulin and C-peptide decreased by 29-38% and 41-46%
respectively. A negative correlation between alterations in plasma
C-peptide or insulin and IGFBP-1 was observed at most time
intervals, but except for the correlation between C-peptide and
IGFBP-1 at day 15 (P < 0.05) none of these correlations was of
statistical significance.
IGFBP-3 was evaluated by Western ligand blots and
immunoblots in addition to RIA (Table 2). Densitometric scanning
of ligand blots revealed a mean decrease in intact IGFBP-3
between 26% and 49%. This decrease was somewhat larger than
that observed in total IGFBP-3 evaluated using RIA. Although we
observed only a minor overall increase in the ratio of fragmented
to intact IGFBP-3 and in IGFBP-3 protease activity, several
patients had a substantially higher ratio of fragmented to intact
IGFBP-3 in the samples obtained at the time when disease
progression was recorded (Figure 2). A positive correlation
between the decrease in IGF-I and -H plasma levels and increase in
fragmented to intact IGFBP-3 was found at all time interval.
but it was of statistical significance only on day 57 (P < 0.05).
Densitometric scanning of low-molecular-weight IGFBPs on the
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Figuire 3 IGF-1, IGF-11 and IGFBP-3 levels measured usii
receivng only oneinjection with ocfteotide before term*in
patient had a slow cisease progression and minor change
proteaseactivity until day 84
ligand blot did not reveal any alterations apart fr
(significant at days 29 and 57) increase from 19
36-kDa band representing IGFBP-2 (data not sho
One patient received only one injection of o
patient all parameters retuned to baseline levels at
DISCUSSION
Although previous somatostatin analogue formul
found to be generally well tolerated, two to three i
were required because of their short half-lives (I
Plasma steady-state octreotide concentrations ofC
are reported to cause a 70-80% inhibition of ar}
growth hormone secretion in healthy humans
1992). However, much higher plasma levels of
500 ng ml-') have been reported to be necessary
vivo growth inhibition of colon cancer xenogra
(Dy et al, 1992). The lowest value of octreot
individual patients during treatment in our study
whereas the mean levels for each cohort were cor
at different time intervals. Moderate variations
and low peak concentrations suggest adequate d
i.m. administered octreotide pamoate. Although t
all patients achieve plasma octreotide levels suffic
GH suppression in healthy individuals, the coi
different in patients suffering from advance
patients have been reported to have eleva
(Emermann et al, 1984; Klijn et al, 1990). The stel
mean plasma levels of octreotide in cohorts 2 1
weeks) and 3 (160mg every 2 weeks) until day
steady state was not reached before terminating
tion in the majority of the patients. Owing tc
absorption from the depot formnulation, and the
drug availability after OncoLAR administratioi
common pharmacokinetic variables such as te
clearance rate and volume of distribution could n
in this study.
We found octreode pamoate administered in doses up to
160 mg every second week to be well tolerated in patients with
advanced cancer. The overall incidence of side-effects was low in
all cohorts, and no grade 3 side-effects were observed.
Treatment with octreotide pamoate had pronounced effects on
the IGF system. The 50% decrease in plasma levels of IGF-I is in
accordance with recent reports on somatuline (Figg et al, 1995)
and lanreotide (di Leo et al, 1995) as well as a previous study with
octreotide (Pollak et al, 1989). Mean baseline levels of IGF-1
(65 ng ml-') and IGF-H (275 ngml-') were much lower than the
normal range of these peptides (IGF-1; 100-494 ng ml-' and IGF-
IGF-I I1; 462-1042 ng ml-')used as reference by others (Lawrence et al, *@-- IGF-lI 1997). This may be explained partly by advanced age as well as
*U- BP-3 weight loss in our patients, both known to decrease plasma IGF-I
levels (Sara and Hall, 1990). It cannot be excluded that some ofthe
futher decrease in IGF-I andIGF-HI observed beyond day 15 may 80 100 be due to disease-related factors, but only a minority of patients
experienced major weight loss or deteriorating liver function.
ingR napaent Tedropinplasma IGF-ImaybeduetoinhibitionofGH secre- mtm Pne The tion by octreotide causing decreased hepatic synthesis of this s in the IGFBP-3 growth factor (Schwander et al, 1983), but other mechanisms may
also operate (Serri etal, 1992). The observed 27-37% decrease in
IGF-ll levels was unexpected, as previous studies with the somato-
statin analogue somatuline (Figg et al, 1995) as well as other om a progressive hormonal therapies influencing IGF-I levels (Frost et al, 1996;
% to 40% in the Reed et al, 1992) were found to have no effects on IGF-H. We lwn). speculate that some of the decrease in IGF-ll levels may be
ctro ide. In this secondary to a GH-dependent decrease in IGFBP-3 in our patients.
d ay 84 (Figure 3). GH is the most important regulator for synthesis of ALS (Dai et al,
1994), which, together with IGFBP-3, is necessary for formation
ofthe 150-kDa ternary complex. A decrease in ALS (not evaluated
in our study) affecting formation of the terary complex may l ations have been subsequently reduce the amount of IGFBP-3 as well as available
i njections per day binding sites for IGFs in this complex. The possible explanation
K utz et al. 1986). may he that low-molecular-weight complexes consisting of only
.27-0.55 ng ml-' IGF-I or-i and an IGF-binding protein (including IGFBP-3) have
paine-stimulated a shorter half-life than the ternary complex (Guler et al, 1989). The
(Marbach et al, decrease in IGFBP-3 is probably not secondary to the fall in IGF-1,
octreotide (about as a previous study has shown that although administration of GH
for significant in increases plasma IGFBP-3 levels it was decreased by administra-
fts in nude mice tion of IGF-I (Kupfer et al, 1992).
ide measured in Although most of the observed alterations in IGF-1, -II and
was 3.4 ng ml-', IGFBP-3 may be explained by effects of uratment with octreotide,
isiderably higher an increase in IGFBP-3 protease activity related to disease
in plasma levels progression may also influence these parameters. Although total
lepot function of IGFBP-3 determined using RIA decreased by 15-20% only,
this suggests that densitometric scanning of IGFBP-3 on WLB revealed a larger
- ient for effective suppression of intact IGFBP-3 (26-49%). Most IGFBP-3 RIAs
nditions may
be
detect both intact IGFBP-3 as well
as fragments,
and the observed
cancer, as many increase in IGFBP-3 protease activity is not reflected by the RIA
ited
GH levels results. Discrepancies between RIA and have also been
pwise increase in observed by others (Gargosky et al, 1992), indicating the impor-
(160 mg every 4 tance of evaluating IGFBP-3 also by WLB and immunoblots. The
57 indicates that decrease in IGF-I and -H was also positively correlated with an
drug administra- increase in IGFBP-3 fragmentation at day 57, indicating that alter-
the continuous ations in IGFBP-3 protease activity may also influence plasma
fact that plasma levels of IGF-I and -H. An increase in IGFBP-3 protease activity
n
is not known, been reported to increase plasma clearance in IGF-I in rats
.rminal
half-life, (Davenport et al, 1990). Alternatively,
the increase in IGFBP-3
l otbe determined protease activity may have been a compensatory response to the
fall in plasma IGF-I and IGF-H in order to maintain availability of
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IGFs to the tissues. The IGFBP-3 protease activity has been
reprted to be high in GH-deficient patients and low in acme-
galic patients, consistent with an inverse relationship with IGF-
levels (Lassarre et al, 1994).
Our finding of an increase in fasting plasma levels ofIGFBP-l
is in accordance with the findings of others (Ezzat et al, 1992;
Wolthers etal, 1994). PlasmaIGFBP-1 isinversely correlated with
insulin levels in healthy subjects, and insulin is known tobe one of
the most important regulators of plasma IGF'BP-I (Holly et al,
1988). Data from some studies indicate an insuln-independent
regulation of IGFBP-l by somatostatin analogues (Ezzat et al,
1992; Wolthers et al, 1994). However, other investigators have
reported an inverse correlation between insulin and IGFBP-l also
during reatment with octreoide (Fredstorp et al, 1994), and
hyperinsulinaemia was found to abolish somatostatin-stimulated
IGFBP-1 release (0rskov etal, 1994). In this study, fasting plasma
levels of both insulin and C-peptide were significantly decreased
and correlated negatively with alterations in plasma levels of
IGFBP-1. Thus, our data support a role ofinsulin in the regulation
of IGFBP-1 during treatment with octreotide. It is difficult to
assess the influence of an increase in IGFBP-1 on the biological
actions of IGF-I as this binding protein may inhibit but also
enhance IGF-I effects in vivo, depending on the phosphorylation
status ofthis binding protein (Jyung et al, 1994).
Densitometric scanning ofWLB revealed an increase in the 36-
kDa bandcorresponding to IGFBP-2. In aprevious study, IGFBP-
2 was found to be increased in many cancer patients (Kanety et al,
1993), and it is possible that the increase in this binding protein
observedduring tratment maybe associated with disease progres-
sion rather than any influence ofdrug treatment.
Somatostatin analogues are known to inhibit GH secretion (del
Pozo et aL 1986). Surprisingly, we did not observe a consistent
suppression ofurinary GH in ourpatients. Urinary 12-h GH secre-
tion was measured using a sensitive RIA, and previous studies
have shown a good correlation between urinary GH secretion and
plasma GH profile (Girard and Fischer-Wasels, 1990; Hourd and
Edvards, 1989). However, only a small amount (< 0.01%) of
plasma GH is normally excreted in the urine (Baumann and
Abramson, 1983), and whether this fraction may change in
patients with advanced cancer is not known. We observed particu-
larly high values in the last urinary samples obtained in patients
with rapid progressive disease. Thus, the validity of urinary GH
measurements in patients suffering from advanced cancer may be
questionable. But it is also possible that no clinically significant
suppression ofplasmaGH isobtained bytreatment with octreotide
in these patients as has been observedby others (Klijn et al, 1990).
In conclusion, octreotide pamoate in doses up to 160 mg every
second week provides high plasma drug levels and is well toler-
ated inpatients with advanced cancer. All doses administered were
found to significantly suppress plasma levels of IGF-I, IGF-II,
IGFBP-3, insulin and C-peptide, and to increase plasma levels of
IGFBP-1. Whether suppression ofplasma IGF-I and -II may be of
importance regarding tumour growth is not yet clear. The durable
endocrine effects and clinical tolerance suggest that octreide
administered as its pamoate depot formulation should be evaluated
in further trials in cancer patients.
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